NuCana PLC Sponsored ADR (NASDAQ:NCNA) – Stock analysts at Jefferies Group issued their Q3 2017 EPS estimates for shares of NuCana PLC Sponsored ADR in a research note issued to investors on Monday. Jefferies Group analyst E. Yang anticipates that the company will earn ($0.04) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for NuCana PLC Sponsored ADR’s Q4 2017 earnings at ($0.16) EPS, FY2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.41) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($1.43) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($1.50) EPS and FY2021 earnings at $2.82 EPS.

Other research analysts also recently issued reports about the company. William Blair began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They issued an “outperform” rating for the company. Citigroup Inc. began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They issued a “buy” rating and a $23.00 price target for the company. Finally, Cowen and Company began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They issued an “outperform” rating for the company.

TRADEMARK VIOLATION WARNING: “Equities Analysts Issue Forecasts for NuCana PLC Sponsored ADR’s Q3 2017 Earnings (NCNA)” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/25/equities-analysts-issue-forecasts-for-nucana-plc-sponsored-adrs-q3-2017-earnings-ncna.html.

NuCana PLC Sponsored ADR (NASDAQ NCNA) opened at 13.80 on Wednesday. The company’s market capitalization is $438.99 million. The stock has a 50 day moving average of $15.83 and a 200-day moving average of $15.83. NuCana PLC Sponsored ADR has a 52-week low of $13.05 and a 52-week high of $19.95.

NuCana PLC Sponsored ADR Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Earnings History and Estimates for NuCana PLC Sponsored ADR (NASDAQ:NCNA)

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.